This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CONMED (CNMD) Q1 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
CONMED Corporation (CNMD) reported first-quarter 2017 adjusted earnings of 38 cents per share, beating the Zacks Consensus Estimate by 4 cents.
Stryker (SYK) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Stryker Corp (SYK) reported adjusted earnings of $1.48 per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate by 5 cents.
Centene (CNC) Beats Q1 Earnings on HealthNet Acquisition
by Zacks Equity Research
Centene Inc. (CNC) reported first-quarter 2017 adjusted net income per share of $1.12 cents, which beat the Zacks Consensus Estimate by 5.7%.
Merit Medical (MMSI) Closes 5.2M Follow-On Share Offering
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) announced that it has closed its follow-on public offering of 5.2 million shares of common stock at $28.25 per share.
Akers Receives Cholesterol Test Kit Order from First Check
by Zacks Equity Research
Akers Biosciences, Inc. (AKER) announced that it has received an initial order under the distribution agreement for its rapid cholesterol self-test kit.
Henry Schein (HSIC) Poised on Solid Growth, Risks Remain
by Zacks Equity Research
On Mar 27, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
BioScrip (BIOS) Stock Declines on Dull Q1 EBITDA Outlook
by Zacks Equity Research
Bioscrip, Inc.'s (BIOS) shares witnessed a 2.2% fall in yesterday's trading session, closing at $1.78.
Evolent Health (EVH) Prices 7.5M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) announced the pricing of its follow-on public offering of 7.5 million shares of Class A common stock at $21.25 per share.
LifePoint Grows Inorganically Yet Stock Suffers: Here's Why
by Zacks Equity Research
Despite its efforts to grow inorganically, LifePoint's shares returned 15.2% compared with a 31% gain for the Zacks categorized Medical Hospital industry over the past three years.
DexCom Gains as CMS Announces Criteria for G5 Mobile CGM
by Zacks Equity Research
The Centers for Medicare & Medicaid Services published an article clarifying the criteria for coverage of its DexCom (DXCM) G5 Mobile CGM system for patients with diabetes and on intensive insulin therapy.
Medidata Clinical Cloud Selected for AML Master Trial by LLS
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) announced that The Leukemia & Lymphoma Society selected Medidata Clinical Cloud platform for diagnosis and treatment of acute myeloid leukemia (AML) through a clinical trial known as the Beat AML Master Trial.
The Cooper Companies Hits 52-Week High on Multiple Positives
by Zacks Equity Research
Shares of Pleasanton, CA-based The Cooper Companies (COO) rallied to a new 52-week high of $202.70 on Mar 23, closing a tad lower at $199.70.
Merit Medical (MMSI) Prices 4.5M Follow-On Share Offering
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) announced that it has priced its follow-on public offering of 4.5 million shares of common stock at $28.25 per share.
Should HCA Holdings (HCA) Stock Be in Your Portfolio Now?
by Zacks Equity Research
HCA Holdings Inc. (HCA) stock has gained 8.12% in the last one year, outperforming the Zacks categorized Medical-Hospitals industry, which registered an increase of only 1.26%.
Cooper Companies (COO) Increase Share Repurchase Program
by Zacks Equity Research
The Cooper Companies, Inc. (COO) recently announced that it has approved a $500.0 million increase in its ongoing share repurchase program.
WellCare Health's Revenue Growth Strong, Rising Costs a Drag
by Zacks Equity Research
WellCare Health Plans, Inc. (WCG) stock has long been an investor favorite owing to strong fundamentals.
HealthEquity (HQY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity Inc (HQY) reported earnings of 7 cents per share in the fourth quarter of 2016, higher than the Zacks Consensus Estimate of 5 cents.
DENTSPLY Sirona Grapples with Multiple Issues: Dump Now?
by Zacks Equity Research
On Mar 20, we issued an updated research report on NY-based DENTSPLY Sirona Inc. (XRAY) -- a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.
Neogen (NEOG) Earnings and Revenues Meet Estimates in Q3
by Zacks Equity Research
Neogen Corp (NEOG) reported adjusted earnings of 27 cents per share in the third quarter of fiscal 2017. The figure was in line with the Zacks Consensus Estimate and increased 22.7% from the year-ago quarter.
Merit Medical (MMSI) to Refinance Debt via Share Offering
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) announced that it has commenced a follow on public offering of its common stock.
Mazor Robotics-Medtronic's Mazor X Partnership Strengthens
by Zacks Equity Research
Mazor Robotics (MZOR) recently announced that its strategic partnership with Medtronic Plc. (MDT) for the commercialization and co-promotion of Mazor X platform, an innovative guidance system for spine surgery, is going strong.
Fresenius (FMS) to Jointly Develop Acumen with Epic Systems
by Zacks Equity Research
Fresenius Medical Care AG & Co. KGAA (FMS) announced that it would jointly develop Acumen 2.0 with Epic Systems Corporation.
PharMerica Takes Over CareMed, Expands in Specialty Pharmacy
by Zacks Equity Research
PharMerica Corporation (PMC) recently announced the acquisition of CareMed Specialty Pharmacy, a leading provider of specialty pharmacy services. However, all the other terms of the deal have been kept under wraps.
Air Methods (AIRM) Opens New Training Facility in Colorado
by Zacks Equity Research
Air Methods Corporation (AIRM) announced the opening of new FlightSafety Learning Center in Denver, CO.
Patterson (PDCO) Rewards Shareholders with 8% Dividend Hike
by Zacks Equity Research
Patterson Companies Inc. (PDCO) recently hiked its quarterly dividend by 8% to 26 cents per share from 24 cents.